Until 2019 and for 20 years, Dr. Rosenbaum, Stanley Cobb Professor of Psychiatry at Harvard Medical School, chaired a department of 600 clinicians and researchers, and 150 trainees, ranked by U.S. News and World Report as #1 in the United States in 2019 and for 20 of the prior 24 years, with 60 specialty clinical and research programs and over 70 million dollars of annual research spending. At MGH, the nation's largest hospital based research institution, with over 1 billion dollars of annual research, he served as Chair of the Executive Committee on Research. 2007 recipient of the C. Charles Burlingame Award for lifetime achievement in psychiatric research and education, he was 2016 recipient of the Joseph B. Martin Dean's Leadership Award for the Advancement of Women Faculty for Harvard Medical School. Emeritus Fellow of the ACNP, he is a 2018 Ellis Island Medal of Honor awardee. Past President/Board Chair of the Anxiety and Depression Association of America (ADAA), he served as Chair of the Scientific Council, President and Board member of the American Foundation for Suicide Prevention. He served a 6 year term as Trustee of the Massachusetts General Hospital, 3 years as Trustee of the Partners Healthcare System, and now co-Chair of Development at MGH. Co-author of more than 400 original articles and reviews, and editor of 20 books, he led longitudinal studies of children at risk for anxiety disorders and depression, examining behavioral differences, risk factors, longitudinal outcomes, treatment, genetics, and brain structure and function of children of parents with mood and anxiety disorders. He currently is directing the MGH Center for Neuroscience of Psychedelics (CNP), to understand how psychedelics change the brain and to explore novel mechanisms for treatment of psychiatric disorders. He co-founded Psy Therapeutics to advance the discovery of novel drugs for psychiatric and neurologic disorders (www.psythx.com), co-founded Sensorium Therapeutics (www.sensorium.bio), to explore plant derived molecules as leads for novel psychiatric therapeutics, and co-founded Entheos Labs, Inc. to bioengineer novel psychedelic botanicals to deliver a new generation of psychedelic-derived therapeutic molecules. He graduated in 1969 from Yale College and 1973 from Yale Medical School and trained in Psychiatry at Massachusetts General Hospital, Harvard Medical School.